Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
Alzprotect designs and develops innovative therapeutic solutions for these diseases.
Our objective: to slow down or stop neurodegeneration and, where possible, to restore some brain capacities
An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
Lille (France), June 22nd, 2021 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today that Dr. John Tchelingerian has joined the Board of Directors of Alzprotect. Alzprotect is financed by the Xerys Funds.
Dr John Tchelingerian is a serial entrepreneur in life sciences. As a veteran of the industry, he co-founded and/or lead several biotech companies as CEO or Chairman & CEO. He raised a total of over €200 million of funding during his career and achieved together with his teams to bring five drug candidates from research to the clinics (up to phase IIb/III) and realized several international pharmaceuticals partnering and M&A deals. He is currently the Managing Partner and co-founder of two specialized strategic advisory firms, The Connecting Architects and Silver Ocean Ventures and Chairman of Pan-Cancer T’s Supervisory Board. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris.
Dr. John Tchelingerian commented: « I am delighted joining the board of Alzprotect as a Director to contribute to the company’s growth and its success. The company has made remarkable progress since the first time I met Philippe and his team a few years ago. I am convinced that Alzprotect will be a game changer in the field of PSP with its drug-candidate AZP-2006, currently in phase 2a clinical trials in Europe. »
Dr Philippe Verwaerde, President of Alzprotect, declared: "John's profile and experience are valuable assets to strengthen our board of directors on the eve of a strategic inflection point and a rise in development of Ezeprogind / AZP2006 "
Alzprotect and the Rothschild Foundation Hospital announce the signing of a collaboration in a phase 2 clinical trial for the treatment of Progressive Supranuclear Palsy
Lille (France), May 11th - Alzprotect, biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases, and the Adolphe de Rothschild Foundation Hospital announced today the signing of a collaboration agreement. This first materializes with the opening in Paris, within the Rothschild Foundation Hospital of the 3rd clinical center, as part of the phase 2a trial aimed at evaluating the safety of the main drug candidate of the company, EZEPROGIND (AZP2006) for the treatment of progressive supranuclear palsy (PSP). PSP is an orphan disease for which Alzprotect has obtained "orphan drug" status from the Food and Drug Administration (FDA) and the European Medicines Agency. Alzprotect is financed by the Xerys funds.
With EZEPROGIND, Alzprotect mainly targets two neurodegenerative diseases: Progressive Supranuclear Palsy (PSP) for which there is no treatment to date and Alzheimer's disease, recognized as a major public health issue, currently without any reliable early diagnosis or treatment that can modify the course of the disease.
Dr Pierre Le Sourd, member of the Supervisory Board of Xerys Gestion and member of the Board of Directors of Alzprotect, declares “It is our duty at Xerys to invest in companies whose mission is to identify solutions for diseases that are public health priorities. We are proud of this scientific partnership with the Adolphe de Rothschild Foundation Hospital. This is a very strong signal. I would like to thank Mr. Julien Gottsmann as well as all the teams who make it possible to accelerate this project to fight neurodegenerative diseases. "
Monsieur Julien Gottsmann, CEO of the Rothschild Foundation Hospital emphasizes: "The signing of this agreement with the biotechnology company Alzprotect will allow us to jointly conduct a clinical trial to evaluate a treatment against Progressive Supranuclear Palsy. This partnership signed within the framework of Rothschild Medical Development brings hope for treatments to patients suffering from PSP. "
Dr Michael Alexandre Obadia, neurologist at the Rothschild Foundation Hospital adds: "Supra-nuclear paralysis is a severe pathology with a poor prognosis; the development of new therapies is a major issue in this field. I look forward to participating in this ambitious project on behalf of the Hospital and the collaboration that is beginning with the Alzprotect teams. "
Dr Philippe Verwaerde, President of Alzprotect, said: “We are very excited to start this collaboration and to benefit from the internationally recognized expertise of the Rothschild Foundation Hospital and its teams in the field of neurology. The hospital is also monitoring a large number of PSP patients, which will allow us to complete our phase 2a study, and hopefully continue to develop our scientific collaboration. "